.Pharmacolibrary.Drugs.ATC.B.B02BD02

Information

Coagulation factor VIII is a multifunctional glycoprotein playing a crucial role in the blood clotting cascade. It is primarily used for the treatment and prophylaxis of bleeding in individuals with hemophilia A, a genetic deficiency of factor VIII. Factor VIII is approved as a replacement therapy and is administered as either plasma-derived or recombinant concentrate products.

Pharmacokinetics

Pharmacokinetic parameters reported in adult patients with severe hemophilia A who received a single intravenous dose of recombinant factor VIII concentrate.

References

1. Jiménez-Yuste, V, et al., & Møss, J (2015). The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A. Journal of thrombosis and haemostasis : JTH 13(3) 370–379. DOI:10.1111/jth.12816 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25495795

2. Bolon-Larger, M, et al., & Boulieu, R (2007). A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Therapeutic drug monitoring 29(1) 20–26. DOI:10.1097/FTD.0b013e3180311384 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17304146

3. Young, G, et al., & Allen, G (2015). Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. Journal of thrombosis and haemostasis : JTH 13(6) 967–977. DOI:10.1111/jth.12911 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25912075

Revisions

• 06/2025 initial generated model